Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020135870 - CD7 CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92MI CELL AND USE THEREOF

Publication Number WO/2020/135870
Publication Date 02.07.2020
International Application No. PCT/CN2019/129928
International Filing Date 30.12.2019
IPC
C12N 5/10 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/85 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
C12N 15/62 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 2319/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
C12N 2510/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2510Genetically modified cells
Applicants
  • 博生吉医药科技(苏州)有限公司 PERSONGEN BIOTHERAPEUTICS (SUZHOU) CO., LTD. [CN]/[CN]
Inventors
  • 杨林 YANG, Lin
  • 游凤涛 YOU, Fengtao
Agents
  • 上海一平知识产权代理有限公司 XU & PARTNERS, LLC.
Priority Data
201811641769.629.12.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) CD7 CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92MI CELL AND USE THEREOF
(FR) CELLULE NK-92MI MODIFIÉE PAR UN RÉCEPTEUR D'ANTIGÈNE CHIMÈRE CD7 ET SON UTILISATION
(ZH) CD7嵌合抗原受体修饰的NK-92MI细胞及其应用
Abstract
(EN)
The present invention provides a CD7 chimeric antigen receptor-modified NK-92MI cell and use thereof. In particular, the present invention provides an engineered NK cell expressing a chimeric antigen receptor (CAR), said CAR having an antigen-binding domain containing a nanobody VHH sequence targeting CD73. Said NK cell of the present invention can effectively kill tumor cells, especially T cell tumors, and has a good therapeutic effect on T cell leukemia (such as T-ALL).
(FR)
Cellule NK-92MI modifiée par un récepteur d'antigène chimère CD7 et son utilisation En particulier, la présente invention concerne une cellule NK modifiée exprimant un récepteur d'antigène chimère (CAR), ledit CAR ayant un domaine de liaison à L'antigène contenant une séquence VHH de nanocorps ciblant CD73. Ladite cellule NK de la présente invention peut éliminer efficacement des cellules tumorales, en particulier des tumeurs à lymphocytes T, et présente un bon effet thérapeutique contre la leucémie lymphoïde (telle que T-ALL).
(ZH)
本发明提供了CD7嵌合抗原受体修饰的NK-92MI细胞及其应用。具体地,本发明提供了一种工程化的NK细胞,所述的NK细胞表达嵌合抗原受体CAR,所述CAR的抗原结合结构域含有靶向CD7的纳米抗体VHH序列。本发明的NK细胞能够有效地杀伤肿瘤细胞,尤其是T细胞肿瘤,对T细胞白血病(如T-ALL)的治疗效果非常好。
Also published as
Latest bibliographic data on file with the International Bureau